Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

NCT01756924 is registered in ClinicalTrials.gov with Arrevus Inc. as lead sponsor.

NCT NCT01756924
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01756924 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection
Lead sponsor
Arrevus Inc.
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2012
Completion date
July 31, 2014
Enrollment
14 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

infected spacers, prosthetic joint infections of hip, prosthetic joint infections of knee